Previous article Next article

The US Court of Appeals for the Tenth Circuit upholds a District Court decision to dismiss a case alleging exclusionary practices on the grounds that consumer welfare is unaffected and demonstrable intention to exclude in some situations is legitimate (Sanofi-Aventis / Mylan)

On July 29, 2022, the Tenth Circuit [1] affirmed the grant of summary judgment to defendants by the District of Kansas [2] in an important, albeit at times misguided, monopolization opinion. The antitrust claim by Sanofi-Aventis U.S., LLC against Mylan, Inc. and Mylan Specialty, LP, arose from competition (or, perhaps more precisely, a lack thereof) among these pharmaceutical companies in the market for epinephrine autoinjectors (“EAIs”), which are self-administered medical devices used to treat life-threatening allergic reactions. [3] The Tenth Circuit’s opinion may have made at least two fundamental errors, including failing to include any analysis of whether prices in the actual world were lower than in a but-for world (that is, a world without the challenged restraint), as well as

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Gary I. Smith Jr., Debashish Bakshi, The US Court of Appeals for the Tenth Circuit upholds a District Court decision to dismiss a case alleging exclusionary practices on the grounds that consumer welfare is unaffected and demonstrable intention to exclude in some situations is legitimate (Sanofi-Aventis / Mylan), 29 July 2022, e-Competitions Preview, Art. N° 109674

Visites 15

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues